arrow
P

Pingjun Chen

The University of Texas MD Anderson Cancer Center
H指数:19
被引数:1,517

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Spatial Profiling Reveals Distinct Molecular and Immune Evolution of Mouse Lung Adenocarcinoma Precancers with or Without Carcinogen Exposure

空间分析揭示了有或没有致癌物暴露的小鼠肺腺癌前癌的独特分子和免疫进化

2026-01-250
OAAI
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception

人类和小鼠肺腺癌前体物的空间与多组学分析揭示TIM-3可作为癌症拦截的潜在靶点

2025-05-080
OA
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights

通过PET/CT栖息地成像,ctDNA和综合放射基因组学增强NSCLC复发预测-血液见解

2024-04-115
OAAI
Spatial single-cell immune microenvironment analysis reveals the transition from innate to adaptive immune response during early lung adenocarcinoma carcinogenesis
2024-03-220
PRE
Spatial analysis revealed distinct molecular and immune landscape in genetic versus carcinogen-induced lung adenocarcinoma precancer mouse models
2024-03-220
PRE
Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept

CT合成PET改善肺癌的诊断和预后: 概念验证

2024-03-013
OAAI
Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma
2023-12-019
OAAI
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study
2023-07-0127
OAAI
Pathomics reveals the molecular and immune evolution from lung preneoplasia to invasive adenocarcinoma
2023-04-040
PRE
Genomic and clinical predictors of early disease progression and chemoimmunotherapy benefit in advanced NSCLC
2023-04-040
PRE
Tumor volumetric analysis to correlate disease burden with response to dual immune checkpoint blockade in metastatic NSCLC
2023-04-040
PRE
Single cell and spatial profiling reveal molecular and immune evolution from precancers to invasive lung adenocarcinomas in genetic and carcinogen-induced mouse models
2023-04-040
PRE
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer
2023-02-0827
OAAI